241 related articles for article (PubMed ID: 37591216)
21. Current jakinibs for the treatment of rheumatoid arthritis: a systematic review.
Rocha CM; Alves AM; Bettanin BF; Majolo F; Gehringer M; Laufer S; Goettert MI
Inflammopharmacology; 2021 Jun; 29(3):595-615. PubMed ID: 34046798
[TBL] [Abstract][Full Text] [Related]
22. Persistence of Janus-kinase (JAK) inhibitors in rheumatoid arthritis: Australia wide study.
Scheepers L; Yang Y; Chen YL; Jones G
Semin Arthritis Rheum; 2024 Feb; 64():152314. PubMed ID: 38029717
[TBL] [Abstract][Full Text] [Related]
23. Tofacitinib versus methotrexate as the first-line disease-modifying antirheumatic drugs in the treatment of rheumatoid arthritis: An open-label randomized controlled trial.
Khan MM; Ahmed S; Hasan Sajib MK; Morshed AA; Mahbub-Uz-Zaman K; Haq SA
Int J Rheum Dis; 2023 Sep; 26(9):1729-1736. PubMed ID: 37377385
[TBL] [Abstract][Full Text] [Related]
24. Comparative efficacy and safety of 15 and 30 mg upadacitinib administered to patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials.
Song GG; Lee YH
Z Rheumatol; 2020 Feb; 79(1):103-111. PubMed ID: 30725185
[TBL] [Abstract][Full Text] [Related]
25. Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease-modifying anti-rheumatic drugs: a systematic review and network meta-analysis.
Singh JA; Hossain A; Tanjong Ghogomu E; Kotb A; Christensen R; Mudano AS; Maxwell LJ; Shah NP; Tugwell P; Wells GA
Cochrane Database Syst Rev; 2016 May; 2016(5):CD012183. PubMed ID: 27175934
[TBL] [Abstract][Full Text] [Related]
26. Comparison of the efficacy and safety of tofacitinib and peficitinib in patients with active rheumatoid arthritis: A Bayesian network meta-analysis of randomized controlled trials.
Lee YH; Song GG
Int J Rheum Dis; 2020 Jul; 23(7):868-875. PubMed ID: 32483919
[TBL] [Abstract][Full Text] [Related]
27. Baricitinib further enhances disease-modifying effects by uncoupling the link between disease activity and joint structural progression in patients with rheumatoid arthritis.
Lopez-Romero P; de la Torre I; Haladyj E; Aletaha D; Smolen JS
Ann Rheum Dis; 2022 May; 81(5):622-631. PubMed ID: 35193872
[TBL] [Abstract][Full Text] [Related]
28. Discontinuation of methotrexate in rheumatoid arthritis patients achieving clinical remission by treatment with upadacitinib plus methotrexate (DOPPLER study): A study protocol for an interventional, multicenter, open-label and single-arm clinical trial with clinical, ultrasound and biomarker assessments.
Shimizu T; Kawashiri SY; Sato S; Kawazoe Y; Kuroda S; Kawasaki R; Ito Y; Morimoto S; Yamamoto H; Kawakami A
Medicine (Baltimore); 2022 Jan; 101(2):e28463. PubMed ID: 35029189
[TBL] [Abstract][Full Text] [Related]
29. Biologic or tofacitinib monotherapy for rheumatoid arthritis in people with traditional disease-modifying anti-rheumatic drug (DMARD) failure: a Cochrane Systematic Review and network meta-analysis (NMA).
Singh JA; Hossain A; Tanjong Ghogomu E; Mudano AS; Tugwell P; Wells GA
Cochrane Database Syst Rev; 2016 Nov; 11(11):CD012437. PubMed ID: 27855242
[TBL] [Abstract][Full Text] [Related]
30. Comparison of Janus kinase inhibitors in the treatment of rheumatoid arthritis: a systemic literature review.
Jegatheeswaran J; Turk M; Pope JE
Immunotherapy; 2019 Jun; 11(8):737-754. PubMed ID: 30955397
[TBL] [Abstract][Full Text] [Related]
31. Upadacitinib for the treatment of rheumatoid arthritis.
Serhal L; Edwards CJ
Expert Rev Clin Immunol; 2019 Jan; 15(1):13-25. PubMed ID: 30394138
[No Abstract] [Full Text] [Related]
32. Efficacy of baricitinib in patients with moderate-to-severe rheumatoid arthritis with 3 years of treatment: results from a long-term study.
Smolen JS; Xie L; Jia B; Taylor PC; Burmester G; Tanaka Y; Elias A; Cardoso A; Ortmann R; Walls C; Dougados M
Rheumatology (Oxford); 2021 May; 60(5):2256-2266. PubMed ID: 33200220
[TBL] [Abstract][Full Text] [Related]
33. Efficacy of pharmacological treatment in rheumatoid arthritis: a systematic literature research informing the 2019 update of the EULAR recommendations for management of rheumatoid arthritis.
Kerschbaumer A; Sepriano A; Smolen JS; van der Heijde D; Dougados M; van Vollenhoven R; McInnes IB; Bijlsma JWJ; Burmester GR; de Wit M; Falzon L; Landewé R
Ann Rheum Dis; 2020 Jun; 79(6):744-759. PubMed ID: 32033937
[TBL] [Abstract][Full Text] [Related]
34. Comparison of the efficacy and safety of tofacitinib and mavrilimumab in patients with active rheumatoid arthritis: A Bayesian network meta-analysis of randomized controlled trials.
Sung YK; Lee YH
Int J Clin Pharmacol Ther; 2021 Aug; 59(8):557-565. PubMed ID: 33860755
[TBL] [Abstract][Full Text] [Related]
35. Effect of Glucocorticoids on the Clinical and Radiographic Efficacy of Tofacitinib in Patients with Rheumatoid Arthritis: A Posthoc Analysis of Data from 6 Phase III Studies.
Charles-Schoeman C; van der Heijde D; Burmester GR; Nash P; Zerbini CAF; Connell CA; Fan H; Kwok K; Bananis E; Fleischmann R
J Rheumatol; 2018 Feb; 45(2):177-187. PubMed ID: 29142036
[TBL] [Abstract][Full Text] [Related]
36. Comparative Efficacy and Safety of Janus Kinase Inhibitors and Secukinumab in Patients with Active Ankylosing Spondylitis: A Systematic Review and Meta-Analysis.
Lee YH
Pharmacology; 2022; 107(11-12):537-544. PubMed ID: 35817017
[TBL] [Abstract][Full Text] [Related]
37. Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III, Double-Blind, Randomized Controlled Trial.
Fleischmann R; Pangan AL; Song IH; Mysler E; Bessette L; Peterfy C; Durez P; Ostor AJ; Li Y; Zhou Y; Othman AA; Genovese MC
Arthritis Rheumatol; 2019 Nov; 71(11):1788-1800. PubMed ID: 31287230
[TBL] [Abstract][Full Text] [Related]
38. Add-on effectiveness of methotrexate or iguratimod in patients with rheumatoid arthritis exhibiting an inadequate response to Janus kinase inhibitors: The ANSWER cohort study.
Ebina K; Hirano T; Maeda Y; Okita Y; Etani Y; Hirao M; Yamamoto W; Hashimoto M; Murata K; Onishi A; Jinno S; Hara R; Son Y; Amuro H; Kotani T; Shiba H; Katayama M; Yamamoto K; Kumanogoh A; Okada S; Nakata K
Mod Rheumatol; 2023 Jul; 33(4):690-699. PubMed ID: 35962543
[TBL] [Abstract][Full Text] [Related]
39. Upadacitinib for the Treatment of Rheumatoid Arthritis: An Extensive Review.
Boyce EG; Rogan EL; C Lui M
Ann Pharmacother; 2023 Apr; 57(4):450-462. PubMed ID: 35919945
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and Safety of Tofacitinib, Baricitinib, and Upadacitinib for Rheumatoid Arthritis: A Systematic Review and Meta-Analysis.
Wang F; Sun L; Wang S; Davis JM; Matteson EL; Murad MH; Luo F; Vassallo R
Mayo Clin Proc; 2020 Jul; 95(7):1404-1419. PubMed ID: 32499126
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]